Observational study finds genetic similarities between feline and human cancers — Evidence Review
Published in Science, by researchers from Wellcome Sanger Institute, Ontario Veterinary College, University of Bern
Researched by
— the AI search engine for science
Table of Contents
The first large-scale genomic analysis of cat cancers has identified key genetic mutations that closely resemble those found in human cancers, suggesting new avenues for cross-species cancer therapies. Related studies broadly support these findings, highlighting molecular parallels between feline and human mammary tumors and reinforcing the value of cats as comparative models in oncology (1, 2, 3, 4, 5, 9). For more detail, see the original study at Scientific American.
- Multiple studies indicate that feline mammary carcinomas share significant genetic, molecular, and clinical similarities with human breast cancers, including overexpression or mutations in key driver genes such as FBXW7, PIK3CA, and ERBB2/Her2 (2, 5, 9).
- Research on immune checkpoint pathways (such as PD-1/PD-L1 and CTLA-4) in cats has demonstrated comparable mechanisms to those in human cancers, supporting the use of feline models for immunotherapy development (1, 4, 10).
- The role of FBXW7 as a tumor suppressor is well established in human oncology, with its mutations linked to poor prognosis and drug resistance; the new study’s finding of frequent FBXW7 alterations in feline tumors aligns with these earlier human-focused results (11, 12, 13, 14, 15).
Study Overview and Key Findings
Understanding the genetic drivers of cancer in domestic cats is increasingly important as cats are common household pets, often sharing environmental exposures with humans. Prior to this study, the genetic basis of feline cancers was poorly characterized, limiting the development of targeted therapies for cats and reducing the potential for comparative oncology research. By examining tumors from nearly 500 cats across several countries, the research team has provided the first comprehensive map of feline cancer genomics, identifying key similarities with human cancers—including mutations in genes like FBXW7 and PIK3CA—that could inform both veterinary and human cancer treatment strategies.
| Property | Value |
|---|---|
| Study Year | 2022 |
| Organization | Wellcome Sanger Institute, Ontario Veterinary College, University of Bern |
| Journal Name | Science |
| Authors | A. L. Sarver, K. M. Makielski, T. A. DePauw, A. J. Schulte, J. F. Modiano |
| Population | Pet cats with cancer |
| Sample Size | n=500 |
| Methods | Observational Study |
| Outcome | Genetic alterations in feline cancers and their similarity to human cancers |
| Results | Identified 7 driver genes in feline mammary tumors, including FBXW7. |
Literature Review: Related Studies
To assess the broader context of this research, we searched the Consensus database, which includes over 200 million research papers. The following search queries were used to identify relevant literature:
Summary Table of Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How closely do feline mammary tumors resemble human breast cancers? | - Feline mammary tumors display high molecular, genetic, and clinical similarity to human breast cancers, often sharing subtypes and driver gene alterations such as in FBXW7, PI3K/AKT, and ERBB2 (2, 5, 9). - The triple-negative phenotype is more frequent in cats, providing a unique model for aggressive human breast cancer (7, 9). |
| What is the role of immune checkpoint pathways in feline cancers? | - PD-1/PD-L1 and CTLA-4 pathways are active in feline mammary carcinomas, mirroring mechanisms in human cancers and suggesting that immunotherapies developed for humans may also benefit cats (1, 4, 10). - Increased serum levels of immune checkpoint proteins correlate with tumor subtype and progression in both species (1, 4). |
| How does FBXW7 function as a tumor suppressor across species? | - FBXW7 mutations are common in multiple human cancers and correlate with poor prognosis, chemoresistance, and aggressive tumor growth; similar patterns are now identified in feline cancers (11, 12, 13, 14, 15, 6). - Loss of FBXW7 function can synergize with other pathways (e.g., AKT) to drive oncogenesis in both cats and humans (12, 14). |
| What is the comparative oncology value of feline cancers? | - Cats develop spontaneous cancers in shared environments with humans, offering insights into environmental risk factors and cancer biology (7, 8, 9). - Feline cancers, especially mammary carcinoma, are effective preclinical models for testing targeted therapies and understanding metastasis (3, 7, 9). |
How closely do feline mammary tumors resemble human breast cancers?
The new study’s identification of shared driver mutations and molecular pathways between feline mammary carcinoma and human breast cancer reinforces a substantial body of research indicating that cats serve as valuable models for aggressive human breast cancers. This resemblance extends to gene expression profiles, histopathology, and clinical behavior. Notably, the high prevalence of triple-negative subtypes in cats provides unique opportunities for studying therapeutics relevant to difficult-to-treat human cancers (7, 9).
- Feline mammary tumors exhibit amplification and overexpression of genes such as ERBB2/Her2 and TOP2A, paralleling human breast cancer (5).
- Activation of the PI3K/AKT pathway, a common event in both feline and human tumors, is associated with malignancy and poor prognosis (2).
- Gene expression studies confirm that both species share critical molecular targets involved in tumor progression and metastasis (3, 9).
- The spontaneous nature and aggressive phenotype of feline mammary tumors make them particularly informative for translational cancer research (7, 9).
What is the role of immune checkpoint pathways in feline cancers?
Recent studies demonstrate that immune checkpoint proteins—including PD-1, PD-L1, and CTLA-4—are functionally active in feline mammary tumors and are similarly implicated in immune evasion as in human cancers. This supports the potential for cross-species application of immunotherapies and suggests that feline cancers could serve as therapeutic testing grounds (1, 4, 10).
- Serum PD-1/PD-L1 and CTLA-4 levels are elevated in cats with specific mammary carcinoma subtypes, mirroring patterns seen in human patients (1, 4).
- Immunohistochemical studies confirm PD-L1 expression in feline mammary adenocarcinoma and other tumor types (10).
- The molecular conservation of checkpoint proteins between cats and humans highlights the feasibility of developing monoclonal antibodies for feline oncology (1, 10).
- These findings validate the use of spontaneous feline tumors as immunological models for human breast cancer (4, 10).
How does FBXW7 function as a tumor suppressor across species?
The identification of FBXW7 as a frequently mutated driver gene in feline mammary carcinoma aligns with extensive evidence from human oncology, where FBXW7 acts as a critical tumor suppressor. Loss of FBXW7 function is associated with increased tumor aggressiveness, resistance to chemotherapy, and poor clinical outcomes in multiple cancer types (11, 12, 13, 14, 15).
- FBXW7 regulates degradation of key oncoproteins (e.g., cyclin E, c-Myc, Notch), and its mutation leads to unchecked cell growth in both species (11, 12).
- In human breast cancer, FBXW7 mutations are linked to poor prognosis and resistance to certain therapies (11, 15).
- The new cat study’s finding that FBXW7-mutant tumors respond differently to chemotherapy is consistent with observations in human cancers, where FBXW7 status influences drug sensitivity (13, 15).
- Synergistic interactions between FBXW7 loss and activation of other oncogenic pathways (e.g., AKT signaling) have been demonstrated in experimental models (12, 14).
What is the comparative oncology value of feline cancers?
Feline cancers offer unique advantages for comparative oncology due to their spontaneous development, shared environmental exposures with humans, and similar disease progression. This makes cats particularly useful for translational research and for identifying environmental or genetic risk factors relevant to both species (7, 8, 9).
- Studies highlight that cats, like humans, develop cancers in natural settings, enabling the study of gene-environment interactions (7, 8, 9).
- Feline mammary tumors, especially the triple-negative subtype, are more prevalent in cats than in humans, providing a model for aggressive breast cancer research (7, 9).
- Mouse models using feline mammary carcinoma cell lines have been developed to study metastasis and test targeted therapies (3).
- While historical studies have not found a direct link between feline and human cancer incidence within households, the genetic parallels identified in recent genomic studies may inform shared prevention and treatment strategies (8, 9).
Future Research Questions
Although this study provides a comprehensive genomic map of feline cancers and highlights cross-species similarities, several important questions remain. Future research is needed to clarify the functional significance of specific mutations, optimize comparative therapeutic approaches, and further evaluate the translational relevance of feline cancers for human oncology.
| Research Question | Relevance |
|---|---|
| How do FBXW7 mutations affect chemotherapy response in feline and human mammary tumors? | Understanding the impact of FBXW7 on drug sensitivity could inform personalized therapies for both cats and humans, as evidence suggests FBXW7 status influences treatment outcomes (13, 15). |
| What are the functional consequences of PIK3CA mutations in feline cancers? | PIK3CA mutations are common in both feline and human mammary tumors; clarifying their role may guide the use of PI3K inhibitors and improve therapeutic targeting (2, 5, 9). |
| Can immune checkpoint inhibitors developed for humans be effectively applied in cats? | Given the shared PD-1/PD-L1 and CTLA-4 pathways, testing immunotherapies in feline clinical trials could accelerate drug development and benefit both species (1, 4, 10). |
| Do shared environmental exposures between cats and humans contribute to similar cancer mutational signatures? | Investigating environmental risk factors could reveal modifiable exposures influencing cancer risk in both species, a key premise of the comparative oncology approach (7, 8, 9). |
| What therapeutic targets emerge from the genomic comparison of feline and human cancers? | Identifying conserved mutations and pathways may help prioritize targets for drug development and improve the design of cross-species clinical trials (3, 5, 9, 15). |